Lv3
206 积分 2026-05-19 加入
GLP-1 Drugs Linked to Lower Fracture Risk in People With Type 2 Diabetes
1个月前
已完结
The glucagon renaissance in obesity therapeutics
1个月前
已关闭
From adiposity to multisystem morbidity: the case for weight loss as disease modification
1个月前
已完结
Appetite-suppressing effects of GIPR agonism and antagonism work through different brain regions
1个月前
已完结
Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial
1个月前
已完结
Optimal Timing of GLP-1 Receptor Agonist Initiation in Patients with Obesity Eligible for Metabolic Bariatric Surgery
1个月前
已完结
Combination therapy in metabolic dysfunction-associated steatohepatitis
1个月前
已关闭
Beyond weight loss: multisystem benefits of obesity medications
2个月前
已完结
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity
2个月前
已完结
Metabolic implications of hepatic, pancreatic and abdominal adipose tissue depots in Asian Indians across normoglycaemia, prediabetes and type 2 diabetes
2个月前
已完结
皖公网安备34019202002308
